Cardiovascular adverse effects of newer antidepressants

Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052 · see citing works

A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel

Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,422 · see citing works

Sertraline treatment of major depression in patients with acute MI or unstable angina

Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414 · see citing works

Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis

Kemp, A. H., Quintana, D. S., Gray, M. A., Felmingham, K. L., Brown, K., & Gatt, J. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.012 · Cited by 1,286 · see citing works

Heart Rate Variability

van Ravenswaaij‐Arts, C. M. A., Kollee, L. A. A., Hopman, J. C. W., Stoelinga, G. B. A., & van Geijn, H. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-6-199303150-00008 · Cited by 741 · see citing works

Depression and the Course of Coronary Artery Disease

Glassman, A. H., & Shapiro, P. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.4 · Cited by 671 · see citing works

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

Eyding, D., Lelgemann, M., Grouven, U., Härter, M. C., Kromp, M., Kaiser, T., Kerekeş, M., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 591 · see citing works

Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial

Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · see citing works

SERUM VASOCONSTRICTOR (SEROTONIN)

Rapport, M. M., Green, A. A., & Page, I. H. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57137-4 · Cited by 552 · see citing works

Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure

O'Connor, C. M., Jiang, W., Kuchibhatla, M., Silva, S. G., Cuffe, M. S., Callwood, D. D., Zakhary, B., Stough, W. G., Arias, R. M., Rivelli, S. K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.068 · Cited by 535 · see citing works

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

Millan, M. J., Gobert, A., Lejeune, F., Dekeyne, A., Newman‐Tancredi, A., Pasteau, V., Rivet, J., & Cussac, D. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051797 · Cited by 516 · see citing works

Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease

Roose, S. P. (1998) · JAMA · doi:10.1001/jama.279.4.287 · Cited by 455 · see citing works

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · see citing works

Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose

Isbister, G. K., Bowe, S. J., Dawson, A. H., & Whyte, I. M. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 432 · see citing works

Serotonin and Blood Pressure Regulation

Watts, S. W., Morrison, S. F., Davis, R. P., & Barman, S. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004697 · Cited by 396 · see citing works

Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data From 3744 Depressed Patients

Thase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331 · see citing works

5-Hydroxytryptamine receptors in the human cardiovascular system

Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 304 · see citing works

Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding

Andrade, C., Surya, S., Chethan, K. B., & Nagesh, K. S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05786blu · Cited by 302 · see citing works

Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?

Vieweg, W. V. R., Hasnain, M., Howland, R. H., Hettema, J. M., Kogut, C., Wood, M. A., & Pandurangi, A. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.002 · Cited by 269 · see citing works

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard-Andersen, L., Jp, G.-S., Kristensen, M., Refsum, H. E., Øfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258 · see citing works

Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial

Strik, J. J. M. H., Honig, A., Lousberg, R. L., Lousberg, A., Cheriex, E. C., Tuynman-Qua, H. G., Kuijpers, P. M. J. C., Wellens, H. J. J., & van Praag, H. M. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200011000-00007 · Cited by 255 · see citing works

Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease

Roose, S. P., Glassman, A. H., Attia, E., Woodring, S., Giardina, E. V., & Bigger, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.660 · Cited by 212 · see citing works

Reboxetine: tolerability and safety profile in patients with major depression

Tanum, L. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.02606.x · Cited by 198 · see citing works

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

Mago, R., Forero, G., Greenberg, W. M., Gommoll, C., & Chen, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0126-5 · Cited by 195 · see citing works

Drug‐induced long QT syndrome: hERG K+channel block and disruption of protein trafficking by fluoxetine and norfluoxetine

Rajamani, S., Eckhardt, L. L., Valdivia, C. R., Klemens, C. A., Gillman, B. M., Anderson, C. L., Holzem, K. M., Delisle, B. P., Anson, B. D., Makielski, J. C., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706892 · Cited by 193 · see citing works

Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled Trial With Mirtazapine

Honig, A., Kuyper, A. M. G., Schene, A. H., van Melle, J. P., de Jonge, P., Tulner, D. M., Schins, A., Crijns, H. J. G. M., Kuijpers, P. M. J. C., Vossen, H., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31814b260d · Cited by 167 · see citing works

Central cardiovascular regulation and 5-hydroxytryptamine receptors

Ramage, A. G. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00612-8 · Cited by 158 · see citing works

Bupropion for Smokers Hospitalized with Acute Cardiovascular Disease

Rigotti, N. A., Thorndike, A. N., Regan, S., McKool, K. M., Pasternak, R. C., Chang, Y., Swartz, S. H., Torres-Finnerty, N., Emmons, K. M., & Singer, D. E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.04.024 · Cited by 153 · see citing works

Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases

Howell, C., Wilson, A. D., & Waring, W. S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02849.x · Cited by 144 · see citing works

The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance

Darpö, B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00487.x · Cited by 141 · see citing works

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140 · see citing works

An Evaluation of the Cardiovascular Safety Profile of Duloxetine

Wernicke, J., Lled, A., Raskin, J., Kajdasz, D. K., & Wang, F. (2007) · Drug Safety · doi:10.2165/00002018-200730050-00007 · Cited by 131 · see citing works

Psychotropic drugs and the ECG: focus on the QTc interval

Goodnick, P. J., Parra, F., & Jerry, J. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.5.479 · Cited by 120 · see citing works

Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety

Taylor, D. M. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01260.x · Cited by 119 · see citing works

Effects of antidepressant treatment on heart rate variability in major depression: A quantitative review

van Zyl, L. T., Hasegawa, T., & Nagata, K. (2008) · BioPsychoSocial Medicine · doi:10.1186/1751-0759-2-12 · Cited by 118 · see citing works

Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents

Witchel, H. J., Pabbathi, V. K., Hofmann, G., Paul, A. A., & Hancox, J. C. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03320-8 · Cited by 117 · see citing works

The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels

Thomas, D., Gut, B., Wendt‐Nordahl, G., & Kiehn, J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.543 · Cited by 117 · see citing works

Mechanism of Sodium Channel Block by Venlafaxine in Guinea Pig Ventricular Myocytes

Khalifa, M., Daleau, P., & Turgeon, J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35098-0 · Cited by 114 · see citing works

Norepinephrine transporter function and human cardiovascular disease

Schroeder, C., & Jordan, J. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00492.2012 · Cited by 109 · see citing works

Cardiac Safety of Citalopram: Prospective Trials and Retrospective Analyses

Rasmussen, S. L., Overø, K. F., & Tanghøj, P. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00004 · Cited by 105 · see citing works

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Chalon, S., Granier, L., Vandenhende, F., Bieck, P. R., Bymaster, F. P., Joliat, M. J., Hirth, C., & Potter, W. Z. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300209 · Cited by 95 · see citing works

Pharmacokinetic–pharmacodynamic modelling of QT interval prolongation following citalopram overdoses

Friberg, L. E., Isbister, G. K., & Duffull, S. B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02546.x · Cited by 92 · see citing works

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Sambunaris, A., Bose, A., Gommoll, C., Chen, C., Greenberg, W. M., & Sheehan, D. V. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000060 · Cited by 90 · see citing works

A Novel Role for Serotonin in Heart

Nebigil, C. G. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00135-9 · Cited by 90 · see citing works

Cardioprotective Effects of Grape Seed Proanthocyanidins Extracts in Streptozocin Induced Diabetic Rats

Cheng, M., Gao, H., Xu, L., Li, B., Zhang, H., & Li, X. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181379ef6 · Cited by 90 · see citing works

Bupropion exposures: clinical manifestations and medical outcome

Belson, M. G., & Kelley, T. R. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(02)00522-x · Cited by 88 · see citing works

Serotonin and pulmonary hypertension—from bench to bedside?

MacLean, M. R., & Dempsie, Y. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.02.005 · Cited by 85 · see citing works

Antidepressant therapy in patients with ischemic heart disease

Jiang, W., & Davidson, J. R. T. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.041 · Cited by 84 · see citing works

Cardiovascular Variability in Major Depressive Disorder and Effects of Imipramine or Mirtazapine (Org 3770)

Tulen, J. H. M., Bruijn, J. A., de Man, K. J., Pepplinkhuizen, L., van den Meiracker, A. H., & Veld, A. J. M. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00006 · Cited by 81 · see citing works

Pharmacologic Treatment of Depression in Patients With Heart Disease

Roose, S. P., & Miyazaki, M. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000163455.43226.bf · Cited by 76 · see citing works

Specific Serotonin Reuptake Inhibition in Major Depressive Disorder Adversely Affects Novel Markers of Cardiac Risk

Dawood, T., Lambert, É., Barton, D., Laude, D., Elghozi, J., Esler, M., Haikerwal, D., Kaye, D. M., Hotchkin, E., & Lambert, G. W. (2007) · Hypertension Research · doi:10.1291/hypres.30.285 · Cited by 75 · see citing works

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study

Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130040 · Cited by 70 · see citing works

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome

Planer, D., Lev, I., Elitzur, Y., Sharon, N. A., Ouzan, E., Pugatsch, T., Chasid, M., Rom, M., & Lotan, C. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.72 · Cited by 69 · see citing works

Electrocardiogram changes and arrhythmias in venlafaxine overdose

Isbister, G. K. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03382.x · Cited by 68 · see citing works

Double-Blind, Placebo-Controlled Study With Reboxetine in Inpatients With Severe Major Depressive Disorder

Versiani, M., Amin, M., & Chouinard, G. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00006 · Cited by 68 · see citing works

Clinical and ECG Effects of Escitalopram Overdose

van Gorp, F., Whyte, I. M., & Isbister, G. K. (2009) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2009.04.016 · Cited by 66 · see citing works

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

Howland, R. H. (2011) · Drug Safety · doi:10.2165/11593960-000000000-00000 · Cited by 61 · see citing works

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

Clayton, A. H., Kornstein, S. G., Rosas, G. R., Guico‐Pabia, C. J., & Tourian, K. A. (2009) · CNS Spectrums · doi:10.1017/s1092852900020204 · Cited by 59 · see citing works

Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline‐ and methoxamine‐evoked constriction of the dorsal hand vein

Abdelmawla, Langley, Szabadi, & Bradshaw (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00031.x · Cited by 58 · see citing works

QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study

Zhang, L., Chappell, J., Gonzales, C., Small, D. S., Knadler, M. P., Callaghan, J. T., Francis, J. L., Desaiah, D., Leibowitz, M. T., Ereshefsky, L., et al. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318030aff7 · Cited by 58 · see citing works

Clinical use of antidepressant therapy and associated cardiovascular risk

Waring, W. S. (2012) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s28804 · Cited by 58 · see citing works

Sibutramine on Cardiovascular Outcome

Scheen, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s205 · Cited by 55 · see citing works

Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in Newborns

Dubnov‐Raz, G., Juurlink, D. N., Fogelman, R., Merlob, P., Ito, S., Koren, G., & Finkelstein, Y. (2008) · PEDIATRICS · doi:10.1542/peds.2008-0658 · Cited by 55 · see citing works

Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure

Chittaranjan, A., Chethan, K. B., & Surya, S. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32835d735d · Cited by 51 · see citing works

Blood Pressure Changes During Short-Term Fluoxetine Treatment

Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., & Beasley, C. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00004 · Cited by 51 · see citing works

Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder

Mbaya, P., Alam, F. D., Ashim, S., & BENNETT, D. H. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.834 · Cited by 50 · see citing works

The Effects of Venlafaxine on Autonomic Functions in Healthy Volunteers

Siepmann, T., Ziemssen, T., Müeck‐Weymann, M., Kirch, W., & Siepmann, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a255b · Cited by 47 · see citing works

Lack of significant toxicity after mirtazapine overdose: A five-year review of cases admitted to a regional toxicology unit

Waring, W. S., Good, A. M., & Bateman, D. N. (2007) · Clinical Toxicology · doi:10.1080/15563650601005837 · Cited by 46 · see citing works

Serotonin-Induced Hypercontraction Through 5-Hydroxytryptamine 1B Receptors in Atherosclerotic Rabbit Coronary Arteries

Ishida, T., Kawashima, S., Hirata, K., Sakoda, T., Shimokawa, Y., Miwa, Y., Inoue, N., Ueyama, T., Shiomi, M., Akita, H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.9.1289 · Cited by 43 · see citing works

A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension

Thase, M. E., Haight, B. R., Johnson, M. C., Hunt, T., Krishen, A., Fleck, R. J., & Modell, J. G. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172424e · Cited by 39 · see citing works

Heart Failure Worsening and Exacerbation After Venlafaxine and Duloxetine Therapy

Colucci, V. J., & Berry, B. D. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l031 · Cited by 39 · see citing works

The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate

Derby, M. A., Zhang, L., Chappell, J. C., Gonzales, C., Callaghan, J. T., Leibowitz, M. T., Ereshefsky, L., Hoelscher, D. D., Leese, P. T., & Mitchell, M. I. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31804d1cce · Cited by 36 · see citing works

Medically serious adverse effects of newer antidepressants

Mago, R., Mahajan, R., & Thase, M. E. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0041-2 · Cited by 34 · see citing works

Depression and heart disease in US adults

Niranjan-Azadi, A. M., Corujo, A., Ziegelstein, R. C., & Nwulia, E. A. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.01.018 · Cited by 33 · see citing works

Lack of effect of reboxetine on cardiac repolarization

Fleishaker, J. C. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117705 · Cited by 33 · see citing works

5-HT1Dβ Receptor Mediates the Supersensitivity of Isolated Coronary Artery to Serotonin in Variant Angina

Ishida, T., Hirata, K., Sakoda, T., Kanazawa, K., Kawashima, S., Akita, H., & Yokoyama, M. (1998) · CHEST Journal · doi:10.1378/chest.113.1.243 · Cited by 30 · see citing works

Levomilnacipran: a newly approved drug for treatment of major depressive disorder

Mago, R., Mahajan, R., & Thase, M. E. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.889563 · Cited by 29 · see citing works

Selective Serotonin Reuptake Inhibitor Drug Interactions in Patients Receiving Statins

Andrade, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13f08941 · Cited by 28 · see citing works

Antidepressant Augmentation With Anti-Inflammatory Agents

Andrade, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09432 · Cited by 27 · see citing works

Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data

Agelink, M. W., Ullrich, H., Baumann, B., Strum, S., & Majewski, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1146-7 · Cited by 25 · see citing works

Outcomes after Isolated Mirtazapine (Remeron™) Supratherapeutic Ingestions

LoVecchio, F., Riley, B. D., Pizon, A. F., & Brown, M. E. (2007) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2007.03.006 · Cited by 25 · see citing works

Vasoconstrictive effects and SSRIs.

Fricchione, G. L., Woznicki, R., Klesmer, J., & Vlay, S. C. (1993) · PubMed · Cited by 22 · see citing works

What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology

Nutt, D., & Feetam, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110374782 · Cited by 20 · see citing works

Drug Interactions in the Treatment of Depression in Patients With Ischemic Heart Disease

Andrade, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12f08248 · Cited by 16 · see citing works

Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study

Edwards, J. G., Sperry, V., Adams, M. H., Gallipoli, S., Thorn, M. D., Longstreth, J. A., & Boinpally, R. (2013) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201826 · Cited by 13 · see citing works

The central action of the 5‐HT2 receptor agonist 1‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane (DOI) on cardiac inotropy and vascular resistance in the anaesthetized cat

Ramage, A. G., & Daly, M. D. B. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702183 · Cited by 13 · see citing works

Acute and subacute effects of the selective serotonin–noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels

Fischer, F., Vonderlin, N., Seyler, C., Zitron, E., Schernus, B., Katus, H. A., & Scholz, E. P. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0878-8 · Cited by 10 · see citing works

Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs

Andrade, C. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12f08323 · Cited by 9 · see citing works

Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn

Andrade, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12f07731 · Cited by 5 · see citing works

Severe Neurotoxicity Associated With Low-Level Serum Lithium and Risperidone After 25 Years of Uncomplicated Lithium Therapy

Goyal, R., & Ali, Y. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000181 · Cited by 5 · see citing works

[Serotoninergic receptors and cardiovascular diseases].

Hong, E., Castillo, C., Flores, E. E. I., & Mercedes, F. (1994) · PubMed · Cited by 4 · see citing works

Cardiovascular Effects of Duloxetine: Preclinical and Clinical Findings

Detke, M. J., IYENGAR, S., Henck, J. W., Bymaster, F. P., Callaghan, J. T., Knadler, M. P., Chappell, A. S., Wernicke, J., & Thase, M. E. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.012 · Cited by 3 · see citing works

[Vasomotor disorders in the atherosclerotic coronary artery. Are there practical repercussions today?].

Danchin, N., Beurrier, D., Buffet, P., Anconina, J., & Juillière, Y. (1992) · PubMed · Cited by 1 · see citing works

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820 · see citing works

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review

Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · see citing works

Advances in antidepressants for treating post-stroke depression

Paolucci, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1334765 · Cited by 111 · see citing works

Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma

Chaurasiya, N. D., León, F., Muhammad, I., & Tekwani, B. L. (2022) · Molecules · doi:10.3390/molecules27134297 · Cited by 82 · see citing works

Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA)

Yeh, T., Kao, L.-C., Tzeng, N., Kuo, T. B. J., Huang, S., Chang, C.-C., & Chang, H. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.007 · Cited by 72 · see citing works

Agomelatine for the treatment of generalized anxiety disorder

Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61 · see citing works

The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders

Martin, H., Bullich, S., Guiard, B. P., & Fioramonti, X. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12928 · Cited by 48 · see citing works

Psychological and Psychopharmacological Interventions in Psychocardiology

Kahl, K. G., Stapel, B., & Correll, C. U. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.831359 · Cited by 39 · see citing works

Bupleurum in Treatment of Depression Disorder: A Comprehensive Review

Ran, S., Peng, R., Guo, Q., Cui, J., Chen, G., & Wang, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17040512 · Cited by 26 · see citing works

A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management

Joshi, S., Tepper, S. J., Lucas, S. M., Rasmussen, S., & Nelson, R. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14135 · Cited by 28 · see citing works

Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trial

Stewart, J. C., Patel, J. S., Polanka, B. M., Gao, S., Nürnberger, J. I., MacDonald, K. L., Gupta, S. K., Considine, R. V., Kovacs, R. J., Vrany, E. A., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.05.007 · Cited by 26 · see citing works

Unleashing lactoferrin's antidepressant potential through the PI3K/Akt/mTOR pathway in chronic restraint stress rats

Ahmed, H. H., Essam, R. M., El-Yamany, M. F., Ahmed, K. A., & El-Sahar, A. E. (2023) · Food & Function · doi:10.1039/d3fo02222f · Cited by 25 · see citing works

Effects of psychopharmacological treatment with antidepressants on the vascular system

Kahl, K. G., Westhoff‐Bleck, M., & Krüger, T. H. C. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.07.004 · Cited by 23 · see citing works

Direct and indirect effects of psychopharmacological treatment on the cardiovascular system

Kahl, K. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0054 · Cited by 23 · see citing works

A Pathophysiological Intersection of Diabetes and Alzheimer’s Disease

Čater, M., & Hölter, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911562 · Cited by 23 · see citing works

Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative–hypnotics on heart rate variability: Implications for cardiovascular risk

Chang, C.-C., Tzeng, N., Yeh, C., Kuo, T. B. J., Huang, S., & Chang, H. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1294765 · Cited by 20 · see citing works

Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study

Wu, S., Zhou, Y.-F., Xuan, Z.-Z., Xiong, L., Ge, X., Ye, J.-R., Liu, Y., Yuan, L., Xu, Y., Ding, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92807-7 · Cited by 14 · see citing works

TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence

Mizutani, H., Sakakibara, F., Komuro, M., & Sasaki, E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248039 · Cited by 15 · see citing works

Association of Depression Onset and Treatment With Blood Pressure Control After Intracerebral Hemorrhage

Keins, S., Abramson, J. R., Mallick, A., Castello, J. P., Rodriguez-Torres, A., Popescu, D. L., Hoffman, D., Kourkoulis, C. E., Gurol, M. E., Greenberg, S. M., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.040331 · Cited by 13 · see citing works

Management of Psychiatric Disorders in Patients with Cardiovascular Diseases

Gundugurti, P. R., Bhattacharyya, R., & Koneru, A. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_42_22 · Cited by 12 · see citing works

Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant

Hsiao, H., Wang, J. C.-F., & Wu, S. (2022) · Biomedicines · doi:10.3390/biomedicines10061318 · Cited by 10 · see citing works

Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?

Mareti, Ε., Ampatzi, C., Paschou, S. Α., Voziki, E., & Goulis, D. G. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180911104942 · Cited by 8 · see citing works

Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway

Bojanić, I., Bjerkeset, O. A., Williams, L. J., Berk, M., Sund, E. R., & Sletvold, H. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00321-7 · Cited by 8 · see citing works

Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory

Gammoh, O., & Bashatwah, R. M. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/13295 · Cited by 7 · see citing works

Treatment with escitalopram modulates cardiovascular function in rats

Veríssimo, L. F., Volpini, V. L., Estrada, V. B., Matsubara, N. K., Gomes, M. V., Resstel, L. B. M., Corrêa, F. M. D. A., & Pelosi, G. G. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.003 · Cited by 5 · see citing works

The risk for a first acute coronary syndrome in patients treated with different types of antidepressants: A population based nested case-control study

Almog, R., Carasso, S., Lavi, I., & Amir, O. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.04.137 · Cited by 5 · see citing works

Suppressive effect of citalopram on plasma concentrations of thromboxane B2

Richter, T., Alusik, S., Palúch, Z., Burianová, I., Cybulja, A., & Sadilkova, L. K. (2015) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2015.1066848 · Cited by 5 · see citing works

Effect of depression treatment on health behaviors and cardiovascular risk factors in primary care patients with depression and elevated cardiovascular risk: data from the eIMPACT trial

Schuiling, M. D., Shell, A. L., Callahan, C. M., Nürnberger, J. I., MacDonald, K. L., Considine, R. V., Wu, W., Hirsh, A. T., Crawford, C. A., Williams, M. K., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724001429 · Cited by 4 · see citing works

Somatic depression with cognitive impairment in a female patient with hypertension

Volel, B. A., & Troshina, D. V. (2017) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2017-4-60-64 · Cited by 4 · see citing works

Lethal vortioxetine poisoning? A forensic investigation

Zuccarello, P., Carnazza, G., Giorlandino, A., Cosentino, S., Arcifa, V., & Barbera, N. (2023) · Legal Medicine · doi:10.1016/j.legalmed.2023.102314 · Cited by 4 · see citing works

Effect of modernized collaborative care for depression on brain-derived neurotrophic factor (BDNF) and depressive symptom clusters: Data from the eIMPACT trial

Crawford, C. A., Williams, M. K., Shell, A. L., MacDonald, K. L., Considine, R. V., Wu, W., Rand, K. L., & Stewart, J. C. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115581 · Cited by 4 · see citing works

Vortioxetine’s Therapeutic Potential: Cardiac Responses to Chronic Unpredictable Mild Stress in a Rat Model

Özmen, Ö., Taşan, Ş., & Ünal, G. Ö. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240159i · Cited by 3 · see citing works

Risk of antidepressant initiation among users of cardiovascular agents and metformin.

Bojanić, I., Bjerkeset, O. A., Williams, L. J., Berk, M., Bjø‌rngaard, J. H., Sund, E. R., & Sletvold, H. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1078 · Cited by 2 · see citing works

Major psychiatric disorders and the aetiology and progression of coronary heart disease

Jackson, A. C., Barton, D. A., & Murphy, B. M. (2018) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2018.13.9.446 · Cited by 3 · see citing works

Antidepressant prescribing patterns in heart failure patients at residential aged care facilities in Australia: A cross-sectional study

Sim, T. F., Marashdeh, R. M., & Parsons, R. W. (2019) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_18_63 · Cited by 3 · see citing works

Psychopharmacologic treatment

Aga, V. M., Shad, M. U., Zhu, H., & Salzman, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-800136-3.00023-5 · Cited by 2 · see citing works

Ten years of maintenance treatment of severe melancholic depression in an adult woman including discontinuation experiences

Bonnet, U. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2332-6107 · Cited by 1 · see citing works

Effect of depression treatment on subjective sleep components among primary care patients: Data from the eIMPACT trial

Schuiling, M. D., Wu, W., Polanka, B. M., Shell, A. L., Williams, M. K., Crawford, C. A., MacDonald, K. L., Nürnberger, J. I., Callahan, C. M., & Stewart, J. C. (2025) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2025.100132 · Cited by 1 · see citing works

The quercetin-serotonin transporter (SERT) connection: a new hope for depression therapy?

Murthy, M. K. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06889-6 · Cited by 1 · see citing works

Comparative Cardiovascular Safety of Duloxetine and Gabapentin in Patients with Hip Osteoarthritis

Moon, S., Choo, E., Choi, Y. J., & Shin, S. (2025) · Journal of Pain Research · doi:10.2147/jpr.s557621 · Cited by 1 · see citing works

Leisure time physical activity and incident use of prescription tranquilizers: A longitudinal population-based study

Sheikh, M. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.010 · Cited by 1 · see citing works

Psychopharmacological Treatment Issues in HIV/AIDS Psychiatry

Cozza, K. L., Wynn, G. H., Wortmann, G. W., Williams, S. G., & Rein, R. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780199392742.003.0042 · Cited by 1 · see citing works

Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression

Baumann, P., Bertschy, G., Ramseier, F., & Nil, R. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000824 · Cited by 1 · see citing works

Antidepressant Drugs in Elderly

Álamo, C., Lopez-Munoz, F. J., & García‐García, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_29

Agomelatine for treating depression in somatic diseases

Racková, S. (2018) · Praktické lékárenství · doi:10.36290/lek.2018.056

Potencial Terapêutico da Vortioxetina: Respostas Cardíacas ao Estresse Crônico Moderado Imprevisível em um Modelo de Rato

Özmen, Ö., Taşan, Ş., & Ünal, G. Ö. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240159

Антидепрессанты в эпоху кардиометаболической пандемии: от кардиобезопасности к адипоцентричности

Голубев, С. А. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.5.013

Efficacy and safety of GW117 tablets in major depressive disorder: a randomised, double‐blind, placebo‐controlled, phase 2 dose‐finding study

Shen, Y., Hao, X., Shi, X., Tao, Z., Yu, X., Wang, X., Di, X.-L., Hai-bo, Y., Zhang, Y., Li, J., et al. (2025) · General Psychiatry · doi:10.1136/gpsych-2025-102337

Agomelatine and the potential inverse risk of metabolic disorders: a nationwide cohort study with an active comparator design in Taiwan

Wen, Y.-L., Huang, Y.-C., Liao, C.-C., Kao, S., Pan, K., Yang, H.-W., To, S.-Y., Yeh, C. B., & Kao, L. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02130-2

Lavender Oil-Infused Mirtazapine Nanoemulsion for Direct Nose-to-Brain Targeting

Waqar, M. A., Ashfaq, A., Khalid, M., Khan, R., Zahra, S., Alvi, A. S., & Arshad, B. (2026) · BioNanoScience · doi:10.1007/s12668-026-02443-6

Résistance à l’Insuline du Système Sérotoninergique : Implication dans les Troubles de l’Humeur Comorbides au Diabete De Type 2

Martin, H. (2021) · theses.fr (ABES) · doi:10.70675/63526938z3197z4632za668z0b62aa1e8cb8

Sustained Remission in a Patient With Depression, Chronic Insomnia, and Ischemic Heart Disease Using a Combination of Agomelatine and Mirtazapine: A Case Report

Ahmed, M. H., Alhaj, M. A., Khan, S., & Hamid, A. (2026) · Cureus · doi:10.7759/cureus.106520

Signalisation de l'insuline au sein du système sérotoninergique central : nexus de la comorbidité diabète-dépression

Bullich, S. (2021) · theses.fr (ABES) · doi:10.70675/d63a5130zf11dz4a56z9c65za3e7d3844c7d

Diretriz Brasileira de Cardiogeriatria – 2026

Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795

Cardiovascular Effects of Selective Serotonin Reuptake Inhibitors and Other Novel Antidepressants

Khawaja, I. S., & Feinstein, R. E. (2003) · Heart Disease · doi:10.1097/01.hdx.0000061695.97215.64 · Cited by 39 · see citing works

Cardiovascular side effects of newer antidepressants.

Fernandez, A., Bang, S. E., Srivathsan, K., & Vieweg, W. V. R. (2007) · PubMed · Cited by 21 · see citing works

The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases

Behlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 122 · see citing works

Cardiovascular side effects of non-SSRI antidepressants are of concern in high-risk patients

Kang, C. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00927-5

The newer antidepressant drugs and their cardiovascular effects.

Glassman, A. H. (1984) · PubMed · Cited by 32 · see citing works